B. Riley Forecasts Weaker Earnings for Foghorn Therapeutics

Foghorn Therapeutics Inc. (NASDAQ:FHTX) – Stock analysts at B. Riley dropped their Q2 2025 earnings per share (EPS) estimates for shares of Foghorn Therapeutics in a research note issued on Wednesday, May 14th. B. Riley analyst K. Patel now expects that the company will post earnings per share of ($0.36) for the quarter, down from their previous forecast of ($0.32). B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for Foghorn Therapeutics’ current full-year earnings is ($1.55) per share. B. Riley also issued estimates for Foghorn Therapeutics’ Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.49) EPS, FY2026 earnings at ($1.44) EPS and FY2027 earnings at ($1.89) EPS.

Foghorn Therapeutics (NASDAQ:FHTX) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.30). The firm had revenue of $5.95 million for the quarter, compared to the consensus estimate of $4.96 million.

Other analysts have also issued research reports about the stock. JMP Securities reissued a “market outperform” rating and issued a $9.00 price objective on shares of Foghorn Therapeutics in a research report on Thursday, May 15th. Citizens Jmp started coverage on shares of Foghorn Therapeutics in a research note on Wednesday, April 23rd. They issued a “mkt outperform” rating and a $9.00 price target on the stock. Citigroup began coverage on shares of Foghorn Therapeutics in a research report on Wednesday, April 23rd. They set an “outperform” rating on the stock. Finally, HC Wainwright upgraded Foghorn Therapeutics to a “strong-buy” rating in a report on Wednesday, May 14th. One analyst has rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $12.13.

Foghorn Therapeutics Stock Down 1.7%

NASDAQ:FHTX opened at $4.14 on Monday. The company has a market cap of $230.77 million, a P/E ratio of -2.16 and a beta of 3.13. Foghorn Therapeutics has a twelve month low of $2.94 and a twelve month high of $10.25. The business has a 50 day moving average price of $3.96 and a two-hundred day moving average price of $5.11.

Institutional Trading of Foghorn Therapeutics

A number of hedge funds have recently made changes to their positions in FHTX. Lazard Asset Management LLC acquired a new position in shares of Foghorn Therapeutics during the 4th quarter worth approximately $49,000. Cubist Systematic Strategies LLC bought a new position in Foghorn Therapeutics during the fourth quarter worth $51,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Foghorn Therapeutics in the fourth quarter valued at $56,000. BNP Paribas Financial Markets acquired a new position in shares of Foghorn Therapeutics in the fourth quarter valued at $61,000. Finally, AQR Capital Management LLC bought a new position in shares of Foghorn Therapeutics in the first quarter valued at about $68,000. 61.55% of the stock is owned by institutional investors and hedge funds.

About Foghorn Therapeutics

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.